Respiratory tract infections, antibiotic resistance Infections and Infestations
Conditions
Interventions
Group 1 – A Covid/Flu lateral flow test will be performed using a nasal swab. This test takes around 10 mins to perform.
Group 2A – A Covid/Flu lateral flow test will be performed using a nasal swab.
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Age
65 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Age 65 years or over 2. Presenting to primary care with symptoms of a lower respiratory tract infection beginning less than seven days prior to appointment. Symptoms must include an acute cough and one other symptom: 2.1. Shortness of breath 2.2. Sputum 2.3. Chest pain 3. The ability to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Clinical diagnosis of pneumonia 2. Patient is already receiving antibiotics and/or antivirals or has used antibiotics/antivirals in the past 30 days. 3. Patient declines URT swabbing or finger prick blood testing. 4. Patient has cystic fibrosis 5. Patient has bronchiectasis 6. Patient is terminally ill 7. Patient is unable to comply with trial procedures 8. Patient has dementia, and/or is not able to consent themselves to trial procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility outcome measures: 1. Recruitment rate is measured using screening and enrolment logs at monthly timepoints 2. Follow-up rate is measured using returned patient diaries at end of study 3. Withdrawals are measured using study records at end of study 4. Eligibility proportion is measured using screening logs at screening and summarised end of study 5. Compliance – valid test results is measured using CRFs at testing and summarised end of study 6. Compliance – correct number of tests is measured using CRFs at end of study 7. Clinician acceptability is measured using acceptability question in CRF at day of recruitment and summarised end of study 8. Participant acceptability is measured using acceptability question in CRF at day of recruitment and summarised end of study 9. Participant refusal rate is measured using screening logs at approach and summarised end of study | — |
Secondary
| Measure | Time frame |
|---|---|
| Exploratory outcome measures: 1. Antibiotic prescribing is measured using CRF at day of recruitment, within 28 days, and summarised end of study 2. Antiviral prescribing is measured using CRF at day of recruitment, within 28 days, and summarised end of study 3. Change in prescribing due to testing is measured using clinician CRFs at consultation and summarised end of study 4. Time to return to usual activities is measured using patient follow-up diaries recorded daily and summarised end of study 5. Re-consultations is measured using patient follow-up diaries within 28 days from consultation 6. Hospitalisations is measured using patient follow-up diaries within 28 days from consultation | — |
Countries
England, United Kingdom
Contacts
Public ContactJenna Garrod
Outcome results
None listed